Experiential Cases for Empagliflozin & Linagliptin: Listen to Endocrinologist and Diabetologist discuss real life cases of this single pill combination in Indian T2DM patient. This talk aims to provide clinicians an expert perspective with more evidence on the benefits of Empagliflozin and Linagliptin in the management of T2DM patients.
EXCEL - Experiential Cases for Empagliflozin & Linagliptin
Claim This Podcastby Lupin, India
207 episodes
Updated Daily
Accepts GuestsHas Sponsors
Podcast Overview
Experiential Cases for Empagliflozin & Linagliptin: Listen to Endocrinologist and Diabetologist discuss real life cases of this single pill combination in Indian T2DM patient. This talk aims to provide clinicians an expert perspective with more evidence on the benefits of Empagliflozin and Linagliptin in the management of T2DM patients.
Language
🇺🇲
Publishing Since
5/30/2021
2 verified contact emails on file for EXCEL - Experiential Cases for Empagliflozin & Linagliptin
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 12, 2023
A 57-Year-Old Man with Type 2 Diabetes, Hypertension, and Microalbuminuria | Dr. Rachna Hathi Mazumder
<p>Type 2 Diabetes patient with Hypertension and Microalbuminuria is showing clinical features of early changes of renal impairment. Listen to expert to manage inadequately controlled diabetes patients with novel emerging therapies.</p> <p><br></p> <p><br> </p>
June 6, 2023
Diabetic with Established Cardio-Vascular Disease | Dr. Mainak Banerjee
<p>A T2DM patient with prior history of acute vascular event is recently diagnosed with type 2 diabetes mellitus. Listen to the expert to discuss the important aspects to assess and manage such patients.</p> <p><br></p> <p><br> </p>
May 29, 2023
Newly Diagnosed T2D with High Baseline HbA1c Level | Dr. Susovan Halder
<p>A patient with newly detected T2D, came in the clinic with high baseline HbA1c level. Listen to expert the importance of optimum glycemic control early in the disease course for better patient outcome.</p> <p><br></p> <p><br></p> <p><br> </p>
207 total episodes available
Deep-dive analytics for EXCEL - Experiential Cases for Empagliflozin & Linagliptin
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is EXCEL - Experiential Cases for Empagliflozin & Linagliptin?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.